Tonix Pharmaceuticals’ $25 Million Acquisition of FDA-Approved Products from Upsher-Smith Laboratories

Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction.Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two currently-marketed…